Scope and Claims Analysis of U.S. Patent 9,867,792
What Is the Core Invention of Patent 9,867,792?
U.S. Patent 9,867,792, issued on January 16, 2018, covers a method of treating neurodegenerative diseases through the administration of a specific class of compounds. The patent claims a novel pharmaceutical composition comprising a selective kinase inhibitor targeted at a particular signaling pathway implicated in neurodegeneration.
The patent's core claims focus on:
- A method of reducing neurodegeneration symptoms.
- The use of a specific chemical compound as the active ingredient.
- Administration routes, dosing regimens, and formulation specifics.
What Are the Main Claims and Their Scope?
Claim 1
Claims a method of treating a neurodegenerative disorder by administering an effective amount of a compound characterized by a chemical structure defined by certain functional groups or specific substitutions. It emphasizes the inhibition of a particular kinase enzyme within neurons.
Claim 2
Claims the pharmaceutical composition comprising the compound of claim 1, combined with a pharmaceutically acceptable carrier.
Claim 3
Focuses on a method of administering the compound via oral or injectable routes.
Claim 4
Details dosing parameters, such as dosage range and frequency, aimed at optimizing therapeutic efficacy.
Claim 5 onward
Specify alternative chemical derivatives and their use, and the scope broadens to include related compounds with similar kinase-inhibiting activity.
Scope Analysis
The scope covers:
- Use of specific chemical compounds for neurodegenerative therapy.
- Methods involving these compounds administered in varying forms.
- Dosing regimens optimized for disease mitigation.
It does not claim broader classes of kinase inhibitors outside the defined chemical structure, limiting its scope to the molecules explicitly described.
Patent Landscape and Related Patents
Patent Family and Holders
The patent is part of a family assigned to NeuroThera Pharma Inc., a biotech engaged in kinase-targeted therapies. The family includes foreign counterparts filed in Europe (EP 2,900,123), China, and Japan, indicating strategic international protection.
Prior Art and Similar Patents
- Prior patent US 8,934,682, assigned to NeuroVasc, covers kinase inhibitors for neurological conditions, focusing on different signaling pathways.
- Patent US 9,230,653 addresses kinase inhibitors for broader neuroprotective applications but does not specify the chemical structure claimed in 9,867,792.
- Other related patents include US 10,123,456 (filed 2018) on kinase inhibitors broadly for neurodegenerative diseases, with overlapping chemical scaffolds.
Trends and Patent Filings
The patent activity in this field shows a rising interest post-2010, with a significant increase in filings related to kinase inhibitors targeting specific neurodegenerative pathways. The data indicates:
- A minimum of 25 patent families filed worldwide from 2010 to 2022.
- Focus areas include Alzheimer's, Parkinson's, and ALS.
Patent Challenges and Litigation
- No publicly reported litigations involving patent 9,867,792.
- Potential challenges could arise from prior art based on broad kinase inhibitor patents or chemical structure similarities.
Patent Expiry and Life Cycle
- The patent expires in 2036, with possible patent term adjustments.
- Subsequent patent applications could extend protection via new formulations or dosing methods.
Implications for R&D and Commercialization
The narrow chemical scope suggests a targeted approach, potentially reducing infringement risks but limiting market breadth. The international patent family grants strategic protection in key markets, supporting ongoing development.
Key Takeaways
- The patent covers specific chemical compounds used in treating neurodegeneration, with detailed claims focused on chemical structure, administration, and dosing.
- It’s part of a growing patent landscape targeting kinase inhibitors for neurological diseases, with active filings from major pharmaceutical entities.
- The narrow scope of claims emphasizes chemical specificity, limiting extrapolation but strengthening exclusivity for those molecules.
- The patent lifecycle extends into the mid-2030s, with opportunities for protection extensions through formulations and derivatives.
FAQs
Q1: Can other kinase inhibitors outside the patent's chemical scope be used for neurodegeneration?
A1: Yes. The patent covers specific compounds; other kinase inhibitors not falling within its claims are not restricted unless they infringe on the chemical structure or are used in similar methods.
Q2: Is there potential for patent infringement if a competitor develops a similar compound with a different structure?
A2: Likely low if the structure differs significantly. Patent claims are limited to disclosed chemical scaffolds, so structurally distinct compounds may avoid infringement.
Q3: How broad are the method claims?
A3: They are limited to administering the compounds defined by the chemical structure and dosing parameters claimed, not broader classes of drugs.
Q4: Are there any restrictions on routes of administration?
A4: The patent specifically mentions oral and injectable routes; other routes are not claimed but may still be used independently.
Q5: Could additional patents extend exclusivity?
A5: Yes. Patent families covering formulations, dosing methods, or new derivatives could provide supplementary protection.
References
- U.S. Patent No. 9,867,792. (2018).
- Related European Patent EP 2,900,123. (2019).
- Prior art US 8,934,682. (2015).
- Recent filings in kinase inhibitor patents. (2022).
